title: Cell cycle kinetics of hematopoiesis before and after in vivo administration of GM-CSF in refractory anemia: evidence for a shortening of the granulocyte release time.
abstract: GM-CSF administration to patients with refractory anemia (RA) induces an increase in neutrophils and eosinophils. We studied cell kinetic mechanisms underlying this observation using clonogenic assays and in vivo iododeoxyuridine labeling of bone marrow cells. Cell cycle kinetics were studied in three patients before and during GM-CSF administration (two daily subcutaneous injections of 54 or 108 micrograms). No consistent effect on the relative number of bone marrow CFU-GM was noticed. The DNA synthesis time and potential doubling time of low-density bone marrow cells remained essentially the same. A slight decrease (1.5-3.7%) in labeling index was found, originating from the myelo(-mono)cytic lineage. In all three patients the release time of labeled granulocytes from the bone marrow into the peripheral blood was shortened (before GM-CSF treatment 5-7 days and during GM-CSF 3-4 days). Cell cycle kinetics of CD34+ cells were studied in order to obtain kinetic information on immature precursor and progenitor cells. The DNA synthesis time of the CD34+ cells was shortened during GM-CSF therapy, resulting in a shorter potential doubling time. GM-CSF administration to patients with RA results in a rise in granulocytes that might be due partly to an accelerated release of granulocytes from the bone marrow compartment into the circulating blood and partly to an increased proliferative activity of the immature precursor and progenitor cells.
authors.affiliation: Department of Internal Medicine, Division of Hematology, University Hospital Nijmegen, The Netherlands.
authors.forename: P P
authors.initials: PP
authors.lastname: Brons
authors.forename: N
authors.initials: N
authors.lastname: Van der Lely
authors.forename: C
authors.initials: C
authors.lastname: Haanen
authors.forename: A H
authors.initials: AH
authors.lastname: Pennings
authors.forename: J B
authors.initials: JB
authors.lastname: Boezeman
authors.forename: J M
authors.initials: JM
authors.lastname: Wessels
authors.forename: R A
authors.initials: RA
authors.lastname: Raijmakers
authors.forename: T J
authors.initials: TJ
authors.lastname: de Witte
mesh_terms: D000753:Anemia, Refractory / Q000097:blood / Q000503:physiopathology* / Q000628:therapy*; D015703:Antigens, CD / Q000378:metabolism; D018952:Antigens, CD34; D001853:Bone Marrow / Q000378:metabolism / Q000473:pathology; D002453:Cell Cycle; D004247:DNA / Q000378:metabolism; D005260:Female; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000627:therapeutic use*; D006098:Granulocytes / Q000502:physiology*; D006410:Hematopoiesis; D006801:Humans; D007065:Idoxuridine; D008297:Male; D008875:Middle Aged; D016196:S Phase; D013997:Time Factors
chemical_list: D015703:Antigens, CD; D018952:Antigens, CD34; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D004247:DNA; D007065:Idoxuridine